(and dosage form):
One tablet contains 250 mg of the active substance calcium dobesilate.
A. 8.1 Coagulants, haemostatics.
DOXIUM tablets act selectively on the capillary walls regulating their physiological functions of resistance and permeability. This action is beneficial in all cases of capillary fragility due to metabolic disturbances (constitutional or acquired), to surgical stress or induced by certain medicines.
DOXIUM tablets are recommended as the vascular treatment of choice indiabetic retinopathy.
It has been used with good effect as a haemostatic during surgical procedures in otorhinolaryngology, ophthalmology and dentistry.
There are no known contra-indications but on general principles DOXIUM tablets should not be administered during the first trimester of pregnancy.
DOSAGE AND DIRECTIONS FOR USE:
The usual daily dose is 2 to 3 tablets of 250 mg swallowed whole at meals. Duration of treatment may be from one week to several months or longer depending upon the disease condition. Half the above dose is recommended for infants.
SIDE-EFFECTS AND SPECIAL PRECAUTIONS:
Rarely in sensitive persons some nausea or gastric discomfort may occur but this rapidly disappears if the dose is decreased.
KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT:
This has not been encountered. In view of the extremely low toxicity of the medicines no symptoms can be predicted but if poisoning or overdosage is suspected it is recommended on general principles that vomiting be induced or gastric lavage be performed, and such symptomatic supportive therapy be administered as appears indicated.
CONDITIONS OF REGISTRATION:
A white, smooth biconvex tablet of 11,0 mm diameter with the mark "d." engraved on one side.
DOXIUM tablets are supplied in bottles of 100 tablets. Each tablet contains 250 mg calcium dobesilate.
Keep out of reach of children.
Store below 30°C.
Johnson & Johnson Professional Products (Pty) Ltd
(Reg. No. 83/13283/07)
HALFWAY HOUSE, Transvaal
DATE OF PUBLICATION:
12 October 1972.
OM Laboratories Ltd.,
|© Johnson & Johnson
||Code No.: 020040|
SAEPI HOME PAGE
TRADE NAME INDEX
GENERIC NAME INDEX
Information presented by Malahyde Information Systems © Copyright 1996-2000